Singapore medicines with clinical-trial evidence for a new indication

45 of the 966 medicines with a SgTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (11 at L1, 34 at L2), meaning clinical-trial evidence (randomised trials, Phase 2–3 trials or systematic reviews) was found for it.

The medicines come from the registration data of the Health Sciences Authority (HSA), with licence status shown in each drug report; the list reflects the drug reports as last updated on 2026-11-20.

Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.

Medicines with trial evidence (L1–L2)

DrugPredicted new indicationEvidence levelRegistered trials cited (NCT)
BendamustineMantle cell lymphomaL110
BusulfanMyelodysplastic syndromeL110
Clofarabinemyeloid leukemiaL110
ClomipramineAnxiety disorderL1 (with caveat)8
DoxorubicinEwing sarcomaL115
KetamineHeadache disorderL1 (with caveat)8
NepafenacEye diseaseL110
OfatumumabFollicular lymphomaL1 (with caveat)12
Peginterferon Alfa-2AHepatitis E virus infectionL110
PolidocanolEsophageal varices with bleedingL1 (with caveat)0
TacrolimusSeborrheic dermatitisL1 (with caveat)2
AcetylcysteineThrombotic diseaseL27
AtorvastatinHIV infectious diseaseL210
Bupropionattention deficit-hyperactivity disorderL26
ClozapineManic bipolar affective disorderL21
DiazepamInsomnia (disease)L20
DocetaxelEwing sarcomaL28
EverolimusLiposarcomaL2 (with caveat)1
FludarabinePlasma cell myelomaL210
HydrocortisoneAlopecia areataL21
Hydrocortisone AcetateAlopecia areataL21
LedipasvirHepatitis B virus infectionL25
LenalidomideMyeloid leukemiaL211
LevonorgestrelAcne (disease)L20
Mefenamic AcidHeadache disorderL20
MidazolamInsomniaL22
MoclobemideAgoraphobiaL20
MontelukastBronchitisL2 (with caveat)10
Mycophenolate MofetilHIV infectious diseaseL2 (with caveat)4
NortriptylineAttention deficit-hyperactivity disorderL2 (with caveat)0
OxaliplatinMalignant pleural mesotheliomaL23
PazopanibLiposarcomaL26
PimecrolimusSeborrheic dermatitisL21
PrednisoloneAlopecia areataL20
PrednisoneAlopecia areataL20
PropofolMigraine disorderL23
RegorafenibLiposarcomaL2 (with caveat)1
RisankizumabDermatitisL22
RopivacaineMigraine disorderL2 (with caveat)2
SofosbuvirHepatitis B virus infectionL2 (with caveat)11
SunitinibLiposarcomaL22
TocilizumabAnkylosing spondylitisL25
TrimebutineMigraine disorderL2 (with caveat)0
UstekinumabDermatitisL26
VinorelbineEwing sarcomaL23

How to read this list

  • Evidence level follows the site's criteria: L1 = Multiple Phase 3 RCTs; L2 = Single RCT or Phase 2. "(with caveat)" means the drug report qualifies the grade; read the note in the report before relying on it.
  • Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
  • Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
  • For all levels and the full method, see High Evidence (L1-L2), Drug List and the methodology.

Disclaimer
This report is for academic research purposes only and does not constitute medical advice. Please follow physician instructions for medication use. Any drug repurposing decisions require complete clinical validation and regulatory approval.

Reviewer: 藥提醒科技有限公司 (yao.care)